文献速递心境障碍儿童青少年精神

妊娠期及产后锂暴露的安全性及疗效:系统综述与荟萃分析

Lithium Exposure During Pregnancy and the Postpartum Period: A Systematic Review and Meta-Analysis of Safety and Efficacy Outcomes.
PubMed 文献 · Am J Psychiatry · 2019-10-18

该系统综述与随机效应荟萃分析纳入29项研究,评估双相障碍女性妊娠期及产后锂治疗的安全性(主要结局为任何先天畸形)与疗效(主要结局为心境复发预防)。妊娠期锂暴露与任何先天畸形及心脏畸形风险升高相关,妊娠早期暴露与自然流产风险升高相关;锂在预防产后复发方面优于不用锂。血清锂水平<0.64 mEq/L且剂量<600 mg/d的母亲所生新生儿反应性更高,但心脏畸形风险未增加。

要点

  • 妊娠期锂暴露与任何先天畸形(OR=1.81)及心脏畸形(OR=1.86)风险升高相关。
  • 妊娠早期锂暴露与自然流产风险升高相关(OR=3.77)。
  • 锂预防产后复发的效果优于不用锂(OR=0.16,NNT=3)。

核心结论

  • 妊娠期任何时间锂暴露的相关风险较低,但妊娠早期或较高剂量暴露时风险更高。
  • 锂在预防产后复发方面优于不用锂,应个体化权衡安全性与疗效。

研究设计与样本

  • 系统综述与随机效应荟萃分析,评估病例对照、队列及干预性研究。
  • 共纳入29项研究,其中13项可纳入定量分析;采用纽卡斯尔-渥太华量表及Cochrane偏倚风险工具评估质量。

主要发现

  • 妊娠期锂暴露与任何先天畸形风险升高相关(N=23,300,k=11;患病率=4.1%,k=11;OR=1.81,95%CI=1.35-2.41;NNH=33,95%CI=22-77)。
  • 妊娠期锂暴露与心脏畸形风险升高相关(N=1,348,475,k=12;患病率=1.2%,k=9;OR=1.86,95%CI=1.16-2.96;NNH=71,95%CI=48-167)。
  • 妊娠早期锂暴露与自然流产风险升高相关(N=1,289,k=3;患病率=8.1%;OR=3.77,95%CI=1.15-12.39;NNH=15,95%CI=8-111)。
  • 锂预防产后复发的效果优于不用锂(N=48,k=2;OR=0.16,95%CI=0.03-0.89;NNT=3,95%CI=1-12)。
  • 定性合成显示,血清锂水平<0.64 mEq/L且剂量<600 mg/d的母亲所生新生儿反应性更高,但心脏畸形风险未增加。

关键数值与推荐

  • 妊娠期锂暴露与任何先天畸形的OR=1.81(95%CI=1.35-2.41),NNH=33(95%CI=22-77)。
  • 妊娠期锂暴露与心脏畸形的OR=1.86(95%CI=1.16-2.96),NNH=71(95%CI=48-167)。
  • 妊娠早期锂暴露与自然流产的OR=3.77(95%CI=1.15-12.39),NNH=15(95%CI=8-111)。
  • 锂预防产后复发的OR=0.16(95%CI=0.03-0.89),NNT=3(95%CI=1-12)。
  • 血清锂水平<0.64 mEq/L且剂量<600 mg/d时新生儿反应性更高,心脏畸形风险未增加。

临床怎么用

  • 理想情况下应在双相障碍缓解期计划妊娠,并在整个妊娠期使用最低有效治疗范围的锂剂量。
  • 尤其关注妊娠早期及分娩前数日的锂暴露,个体化平衡安全性与疗效。

局限性

  • 29项研究中20项质量良好、6项质量差;1项偏倚风险不明确,2项高偏倚风险。
  • 仅13项研究可纳入定量分析,部分结局的样本量及研究数有限。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: Uncertainty surrounds the risks of lithium use during pregnancy in women with bipolar disorder. The authors sought to provide a critical appraisal of the evidence related to the efficacy and safety of lithium treatment during the peripartum period, focusing on women with bipolar disorder and their offspring. METHODS: The authors conducted a systematic review and random-effects meta-analysis assessing case-control, cohort, and interventional studies reporting on the safety (primary outcome, any congenital anomaly) or efficacy (primary outcome, mood relapse prevention) of lithium treatment during pregnancy and the postpartum period. The Newcastle-Ottawa Scale and the Cochrane risk of bias tools were used to assess the quality of available PubMed and Scopus records through October 2018. RESULTS: Twenty-nine studies were included in the analyses (20 studies were of good quality, and six were of poor quality; one study had an unclear risk of bias, and two had a high risk of bias). Thirteen of the 29 studies could be included in the quantitative analysis. Lithium prescribed during pregnancy was associated with higher odds of any congenital anomaly (N=23,300, k=11; prevalence=4.1%, k=11; odds ratio=1.81, 95% CI=1.35-2.41; number needed to harm (NNH)=33, 95% CI=22-77) and of cardiac anomalies (N=1,348,475, k=12; prevalence=1.2%, k=9; odds ratio=1.86, 95% CI=1.16-2.96; NNH=71, 95% CI=48-167). Lithium exposure during the first trimester was associated with higher odds of spontaneous abortion (N=1,289, k=3, prevalence=8.1%; odds ratio=3.77, 95% CI=1.15-12.39; NNH=15, 95% CI=8-111). Comparing lithium-exposed with unexposed pregnancies, significance remained for any malformation (exposure during any pregnancy period or the first trimester) and cardiac malformations (exposure during the first trimester), but not for spontaneous abortion (exposure during the first trimester) and cardiac malformations (exposure during any pregnancy period). Lithium was more effective than no lithium in preventing postpartum relapse (N=48, k=2; odds ratio=0.16, 95% CI=0.03-0.89; number needed to treat=3, 95% CI=1-12). The qualitative synthesis showed that mothers with serum lithium levels <0.64 mEq/L and dosages <600 mg/day had more reactive newborns without an increased risk of cardiac malformations. CONCLUSIONS: The risk associated with lithium exposure at any time during pregnancy is low, and the risk is higher for first-trimester or higher-dosage exposure. Ideally, pregnancy should be planned during remission from bipolar disorder and lithium prescribed within the lowest therapeutic range throughout pregnancy, particularly during the first trimester and the days immediately preceding delivery, balancing the safety and efficacy profile for the individual patient.

来源:Am J Psychiatry,查看原文。版权归原作者所有。

引用

  1. Fornaro M, Maritan E, Ferranti R, et al. Lithium Exposure During Pregnancy and the Postpartum Period: A Systematic Review and Meta-Analysis of Safety and Efficacy Outcomes. Am J Psychiatry. 2019. PMID: 31623458. doi:10.1176/appi.ajp.2019.19030228

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。